Core Viewpoint - China Resources Medical (01515) expects a decline in profit attributable to shareholders for the year ending December 31, 2025, with estimates ranging from RMB 467 million to RMB 516 million, representing a decrease of approximately 17.5% to 8.9% compared to the estimated profit of RMB 566 million for the year ending December 31, 2024 [1] Financial Performance - The profit attributable to shareholders is expected to decrease by approximately 43.5% to 37.6% when excluding a one-time compensation of about RMB 210 million related to the Yan Hua IOT agreement and corresponding corporate income tax [1] - The decline in profit is less severe compared to a 57.4% drop in profit attributable to shareholders in the first half of 2025, indicating a narrowing of the decline by approximately 13.9 to 19.8 percentage points [1] Operational Challenges - The primary reason for the decline in profit is attributed to a decrease in average medical expenses under the healthcare insurance system, which has negatively impacted the operating profits of member medical institutions [1] - Additionally, the scale of the company's IOT (Investment-Operation-Transfer) business has contracted, further contributing to the decline in profitability [1]
华润医疗(01515)发盈警，预期2025年度股东应占利润约4.67亿元至5.16亿元 同比下降约17.5%至8.9%